Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trial.
(2024 Dec 13)
Lancet HIV
Velloza J, Poovan N, Meisner A, Ndlovu N, Ndimande-Khoza N, Grabow C, Zwane P, Mbele S, Molefe M, Donnell D, Baeten JM, Hosek S, Celum C, Delany-Moretlwe S

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
(2024 Nov 27)
N Engl J Med
Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O, PURPOSE 2 Study Team

Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention.
(2024 Nov 26)
Int J STD AIDS
Peebles K, Matrajt L, Baeten JM, Palanee-Phillips T, Brown ER, MTN-020/ASPIRE Study Team

Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).
(2024 Nov 26)
Clin Infect Dis
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S

Acceptability of six-monthly PrEP dispensing supported with interim HIV self-testing to simplify PrEP delivery in Kenya: findings from qualitative research.
(2024 Oct 24)
BMC Health Serv Res 24(1): 1281
Thuo N, Bardon AR, Mogere P, Kiptinness C, Casmir E, Wairimu N, Owidi E, Okello P, Mugo NR, Baeten JM, Ngure K, Ortblad KF